DAX+0,68 % EUR/USD-0,01 % Gold+0,11 % Öl (Brent)-1,17 %

DGAP-News: QIAGEN N.V. english = - 500 Beiträge pro Seite

Beitrag schreiben

Begriffe und/oder Benutzer


QIAGEN N.V. Invites You to Join Its 2002 Financial Guidance Call on the Web

Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. --------------------------------------------------------------------------------

QIAGEN N.V. Invites You to Join Its 2002 Financial Guidance Call on the Web

VENLO, Netherlands, January 21, 2002 /PRNewswire/ -- In conjunction with QIAGEN´s 2002 Financial Guidance Conference Call, you are invited to listen to the call that will be broadcasted live over the Internet on Thursday, January 24th at 9:30 a.m. (EST)/2:30 p.m. (UK)/3:30 p.m. (Continental Europe), with Metin Colpan, Ph.D., Chief Executive Officer and Peer Schatz, Chief Financial Officer, both of QIAGEN.


QIAGEN -- 2002 Financial Guidance Conference Call When: Thursday, January 24th, 2002 at 9:30 a.m. (EST)/ 2:30 p.m. (UK)/ 3:30 p.m. (CET) Where: www.videonewswire.com/QIAGEN/012402/ How: Live over the Internet -- Simply log on to the web at the address above The corresponding presentation slides will be available to download 30 minutes prior to the start of the call in the investor relations section under http://www.qiagen.com/aboupdf/QIAGEN_012402.pdf Contact: Donald Murphy, Noonan/Russo Communications, 212-696-4455 ext.257 QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia and Canada, believes it is the world´s leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. The Company has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN´s products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, the Company is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,500 people worldwide. Further information on QIAGEN can be found at http://www.QIAGEN.com. . (Minimum Requirements to listen to broadcast: The RealPlayer software, downloadable free from http://www.real.com/products/player/index.html, or The Windows Media Player, downloadable free from www.microsoft.com and at least a 14.4Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to webmaster@vdat.com.) If you are unable to participate during the live webcast, the call will be archived at the following URL: www.videonewswire.com/QIAGEN/050801. CONTACT: Donald Murphy, Noonan/Russo Communications, Inc., 212-696-4455 ext. 257 / Audio: www.videonewswire.com/QIAGEN/050801 end of message, (c)DGAP 21.01.2002 -------------------------------------------------------------------------------- WKN: 901626; ISIN: NL0000240000; Index: NEMAX50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, München, Hannover und Stuttgart 212200 Jän 02

Autor: DGAP import (),22:03 21.01.2002

Beitrag zu dieser Diskussion schreiben

Es handelt sich hier um einen ältere Diskussionen, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier ein neue Diskussion.